Back to results
US 2017/0253659 A1Published application
Antibodies to cd40 with enhanced agonist activity
AssigneeThe Rockefeller University
InventorsJeffrey V. Ravetch, Rony Dahan
Life of this patent
Estimating the term…
Abstract
Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Claims15
An isolated antibody, or antigen binding portion thereof, that
- (i) specifically binds to human CD40
- (ii) comprises a mutant Fc region having one or more mutations corresponding to one or more mutations in an IgG havey chain selected from the group consisting of SEQ ID Nos:
- 3-7, wherein the antibody competes for binding to human CD40 with CP-870,893 or ChiLob, 2141.
Dependencies are inferred from the claim text.